[{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Barclays","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Barclays","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Barclays"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Crown Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Crown Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Crown Laboratories"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Athyrium Capital"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Crown Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0.92000000000000004,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0.92000000000000004,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Crown Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Crown Laboratories"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Syneos Health"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Syneos Health"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Viatris","highestDevelopmentStatusID":"1","companyTruncated":"Revance Therapeutics \/ Viatris"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Revance Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The combined company's flagship brands will include DAXXIFY (daxibotulinumtoxinA-lanm), an acetylcholine release inhibitor and neuromuscular blocking agent.

                          Product Name : Daxxify

                          Product Type : Protein

                          Upfront Cash : $924.0 million

                          February 07, 2025

                          Lead Product(s) : Daxibotulinumtoxin A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Crown Laboratories

                          Deal Size : $924.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Combined company's flagship brands will include DAXXIFY (daxibotulinumtoxinA-lanm), an acetylcholine release inhibitor and neuromuscular blocking agent.

                          Product Name : Daxxify

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          December 08, 2024

                          Lead Product(s) : Daxibotulinumtoxin A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Crown Laboratories

                          Deal Size : $924.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Daxiffy (daxibotulinumtoxinA-lanm) is an acetylcholine release inhibitor and neuromuscular blocking agent. It is being evaluated in Phase 3 clinical trials for cervical dystonia in adults.

                          Product Name : Daxxify

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          September 05, 2024

                          Lead Product(s) : Daxibotulinumtoxin A

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The company aims to advance the commercial growth of its aesthetics portfolio, including DAXXIFY (daxibotulinumtoxinA-Lanm) for moderate to severe glabellar lines.

                          Product Name : Daxxify

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          April 03, 2024

                          Lead Product(s) : Daxibotulinumtoxin A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Barclays

                          Deal Size : $100.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Daxiffy (daxibotulinumtoxinA-lanm) is an acetylcholine release inhibitor and neuromuscular blocking agent. It is being evaluated in Phase 3 clinical trials for cervical dystonia in adults.

                          Product Name : Daxxify

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          February 02, 2024

                          Lead Product(s) : Daxibotulinumtoxin A

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Daxxify® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator or procerus muscle activity...

                          Product Name : Daxxify

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          September 01, 2023

                          Lead Product(s) : Daxibotulinumtoxin A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Daxxify (daxibotulinumtoxina-lanm) for injection is the first and only peptide-formulated, long-lasting neuromodulator, designed for the treatment of cervical dystonia in adults.

                          Product Name : Daxxify

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 14, 2023

                          Lead Product(s) : Daxibotulinumtoxin A

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Daxxify® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator or procerus muscle activity...

                          Product Name : Daxxify

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          February 23, 2023

                          Lead Product(s) : Daxibotulinumtoxin A

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The Company intends to use the net proceeds from the offering to fund the commercialization of DAXXIFY (DaxibotulinumtoxinA-lanm), the RHA® Collection of dermal fillers and OPUL®, and for working capital, research and development and general corporate ...

                          Product Name : Daxxify

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          December 09, 2022

                          Lead Product(s) : Daxibotulinumtoxin A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Goldman Sachs & Co

                          Deal Size : $200.0 million

                          Deal Type : Public Offering

                          blank

                          10

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : DaxibotulinumtoxinA for Injection, an investigational agent not approved by FDA and is currently under regulatory review, combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-ba...

                          Product Name : Daxxify

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 03, 2022

                          Lead Product(s) : Daxibotulinumtoxin A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank